当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析

恒瑞医药

(600276)

  

流通市值:2809.11亿  总市值:2811.23亿
流通股本:63.74亿   总股本:63.79亿

恒瑞医药(600276)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至2024年第一季度实现净利润13.67亿元,每股收益0.21元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至2024年第一季度最新股东权益4243935.53万元,未分配利润3017169.96万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至2024年第一季度最新总资产4634000.14万元,负债390064.60万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入5,997,533,912.1422,819,784,741.3117,013,632,174.6111,168,379,006.13
营业总成本4,412,916,241.6518,214,152,501.7713,258,786,705.298,728,806,054.53
营业利润1,636,008,814.624,909,904,926.213,941,329,512.972,570,209,358.27
利润总额1,502,510,834.524,667,109,690.243,812,376,918.612,512,445,165.18
净利润1,367,488,687.724,277,820,702.53,451,029,827.762,290,405,823.55
其他综合收益-5,925,391.6817,841,438.9314,004,359.1222,513,217.11
综合收益总额1,361,563,296.044,295,662,141.433,465,034,186.882,312,919,040.66
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计33,712,251,970.6531,287,471,171.2130,628,112,709.0729,890,953,637.17
非流动资产合计12,627,749,380.1912,497,035,464.5512,243,278,032.4212,070,379,613.69
资产总计46,340,001,350.8443,784,506,635.7642,871,390,741.4941,961,333,250.86
流动负债合计3,698,071,656.152,553,658,628.062,445,150,681.652,259,969,029.04
非流动负债合计202,574,392.61197,761,566.37219,653,923.56265,499,169.34
负债合计3,900,646,048.762,751,420,194.432,664,804,605.212,525,468,198.38
归属于母公司股东权益合计41,873,504,779.5740,465,795,358.6939,636,900,593.9438,860,607,250.19
股东权益合计42,439,355,302.0841,033,086,441.3340,206,586,136.2839,435,865,052.48
负债和股东权益合计46,340,001,350.8443,784,506,635.7642,871,390,741.4941,961,333,250.86
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计6,136,051,366.9825,455,072,402.0816,456,269,933.1912,145,249,116.94
经营活动现金流出小计4,881,452,457.9817,811,407,327.5612,147,398,752.279,269,900,647.57
经营活动产生的现金流量净额1,254,598,9097,643,665,074.524,308,871,180.922,875,348,469.37
投资活动现金流入小计10,631,618.062,723,192,422.322,610,227,122.21,985,650,059.78
投资活动现金流出小计761,021,859.61,500,877,315.291,372,640,665.79987,443,010.78
投资活动产生的现金流量净额-750,390,241.541,222,315,107.031,237,586,456.41998,207,049
筹资活动现金流入小计-21,100,00021,100,00010,750,470
筹资活动现金流出小计18,134,576.373,165,526,297.543,111,042,990.322,632,565,941.66
筹资活动产生的现金流量净额-18,134,576.37-3,144,426,297.54-3,089,942,990.32-2,621,815,471.66
汇率变动对现金及现金等价物的影响-18,208,185.0112,533,137.6319,695,828.827,703,481.52
现金及现金等价物净增加额467,865,906.085,734,087,021.642,476,210,475.811,279,443,528.23
期末现金及现金等价物余额20,739,390,175.820,271,524,269.7217,013,647,723.8915,816,880,776.31
最新报告期:2024-04-21
研究机构分析师预测每股收益(元)更新日
2023年2024年2025年
德邦证券陈进,李霁阳0.790.991.322024-04-21
东方证券伍云飞0.901.031.212024-04-21
中国银河程培0.790.921.092024-04-21
国联证券夏禹,郑薇0.901.001.202024-04-21
国泰君安丁丹,甘坛焕0.901.081.272024-04-19
TOP↑